Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence and Predictors of Cerebral Microangiopathy Determined by Pulsatility Index in an Asymptomatic Population From the ILERVAS Project

  • Purroy, Francisco|||0000-0002-1808-5968
  • Sánchez, Enric|||0000-0001-7345-1601
  • Lecube, Albert|||0000-0001-9684-0183
  • Arque, Gloria|||0000-0002-8039-3726
  • Vicente-Pascual, Mikel
  • Mauri-Capdevila, Gerard
  • Torreguitart, Núria
  • Hernández García, Marta|||0000-0003-1237-298X
  • Barbé, Ferran|||0000-0002-2340-8928
  • Fernández, Elvira|||0000-0001-5236-1762
  • Pamplona, Reinald|||0000-0003-4337-6107
  • Farràs-Sallés, Cristina|||0000-0001-5956-4116
  • Mauricio, Didac|||0000-0002-2868-0250
  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
Background: Little is known about the prevalence of cerebral microangiopathy (CM), which is related to cognitive impairment, in an asymptomatic population. Pulsatility index (PI) is an easily measurable parameter of cerebral vascular resistance in transcranial duplex of the middle cerebral artery (MCA) study. We aimed to determine the prevalence of CM measured by PI of MCA in low to moderate vascular risk subjects. Methods: We included 3,721 subjects between 45 and 70 years without previous history of vascular disease or diabetes mellitus and with at least one other vascular risk factor from the cross-sectional study ILERVAS (Lleida, Spain). Patients underwent transcranial duplex to determine MCA-PI. Possible CM was defined by MCA-PI.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Development and Validation of a Personalized, Sex-Specific Prediction Algorithm of Severe Atheromatosis in Middle-Aged Asymptomatic Individuals, The ILERVAS Study

  • Bermúdez-López, Marcelino|||0000-0002-3188-4158
  • Martí-Antonio, Manuel
  • Castro-Boqué, Eva|||0000-0002-1013-0007
  • Bretones, María del Mar
  • Farràs-Sallés, Cristina|||0000-0001-5956-4116
  • Torres, Gerard|||0000-0002-1417-7320
  • Pamplona, Reinald|||0000-0003-4337-6107
  • Lecube, Albert|||0000-0001-9684-0183
  • Mauricio, Didac|||0000-0002-2868-0250
  • Valdivielso, José Manuel|||0000-0003-1343-0184
  • Fernández, Elvira|||0000-0001-5236-1762
IIB., Background: Although European guidelines recommend vascular ultrasound for the assessment of cardiovascular risk in low-to-moderate risk individuals, no algorithm properly identifies patients who could benefit from it. The aim of this study is to develop a sex-specific algorithm to identify those patients, especially women who are usually underdiagnosed. Methods: Clinical, anthropometrical, and biochemical data were combined with a 12-territory vascular ultrasound to predict severe atheromatosis (SA: ≥ 3 territories with plaque). A Personalized Algorithm for Severe Atheromatosis Prediction (PASAP-ILERVAS) was obtained by machine learning. Models were trained in the ILERVAS cohort (n = 8,330; 51% women) and validated in the control subpopulation of the NEFRONA cohort (n = 559; 47% women). Performance was compared to the Systematic COronary Risk Evaluation (SCORE) model. Results: The PASAP-ILERVAS is a sex-specific, easy-to-interpret predictive model that stratifies individuals according to their risk of SA in low, intermediate, or high risk. New clinical predictors beyond traditional factors were uncovered. In low- and high-risk (L&H-risk) men, the net reclassification index (NRI) was 0.044 (95% CI: 0.020-0.068), and the integrated discrimination index (IDI) was 0.038 (95% CI: 0.029-0.048) compared to the SCORE. In L&H-risk women, PASAP-ILERVAS showed a significant increase in the area under the curve (AUC, 0.074 (95% CI: 0.062-0.087), p-value: < 0.001), an NRI of 0.193 (95% CI: 0.162-0.224), and an IDI of 0.119 (95% CI: 0.109-0.129). Conclusion: The PASAP-ILERVAS improves SA prediction, especially in women. Thus, it could reduce the number of unnecessary complementary explorations selecting patients for a further imaging study within the intermediate risk group, increasing cost-effectiveness and optimizing health resources. Clinical Trial Registration: [www.ClinicalTrials.gov], identifier [NCT03228459].